December 15, 2025European Heart Journal - Cardiovascular Pharmacotherapy1 citationsOpen Access

SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data

ERElias RawishUniversität Hamburg FLFelicitas LemmerUniversität Hamburg KKKatharina KurzInnsbruck Medical University

Structured PICO

Does the addition of SGLT2 inhibitors to RAAS inhibitors and beta-blockers improve long-term survival in patients with Takotsubo syndrome?

Population

31,018 patients with Takotsubo syndrome diagnosed October 2019-August 2025 from the TriNetX global network

Intervention

SGLT2 inhibitors added to RAAS inhibitors and beta-blockers initiated within ≤72-h post-diagnosis

Comparator

RAAS inhibitors and beta-blockers alone

Outcome

Two-year mortalityhard clinical

In a large real-world cohort of patients with Takotsubo syndrome, the addition of SGLT2 inhibitors to standard therapy was associated with a significant reduction in long-term mortality.

Abstract

AIMS: Takotsubo syndrome (TTS) is an acute cardiac condition marked by transient left ventricular dysfunction. Pharmacological management is largely empirical. SGLT2 inhibitors (SGLT2i) offer cardioprotective effects in other cardiovascular diseases, but their impact in TTS is unclear. We thus aim to evaluate whether SGLT2i improves long-term survival after TTS. METHODS AND RESULTS: We conducted a trial emulation based on real-world data of the TriNetX global network, including patients with TTS diagnosed October 2019-August 2025 (n = 31 018). The primary analysis emulated a de novo pharmacotherapy initiator cohort with a ≤72-h post-diagnosis enrolment window, evaluating the addition of SGLT2i to RAAS inhibitors (RAASi) and beta-blockers (BB). Follow-up began at pharmacotherapy initiation; two-year survival was analysed. Propensity-score matching was performed for age, sex, diabetes, hypertension, dyslipidemia, renal function, initial left ventricular function at diagnosis, and acute severity markers. The median follow-up was 13.3 months. Two-year mortality was 17.5%. After matching (yielding well-balanced 524 patients per group), mortality was significantly reduced in the SGLT2i group compared with RAASi + BB alone (HR 0.56, 95% CI 0.36-0.89). Results were consistent in an extended ≤30-day virtual-enrolment window. A supportive multivariable Cox model considered overall exposure to different therapies (n = 31 018). SGLT2i were associated with the largest reduction in mortality, followed by angiotensin receptor blockers, ACE inhibitors, and BB. Sacubitril/valsartan and MRAs showed no significant association with mortality. CONCLUSION: In the largest real-world TTS cohort, SGLT2i were associated with lower long-term mortality. These findings support their consideration in TTS management and justify randomized trials to evaluate SGLT2i as adjunctive therapy.

Ask AI

Helpful

Bookmark

View Full Paper